Single-arm trial reports orelabrutinib response in high-risk lymphoma
In a prospective, multicenter, single-arm phase II trial conducted at four centers in China, orelabrutinib plus R-CDOP was associated with ...
Tag: BTK inhibitor
The Immune Adaptor MyD88 Emerges as a Double-Edged Sword in Cancer
A new review details how the innate immune adaptor MyD88 both drives and suppresses tumor development across blood cancers and ...
New Leukemia Drug Shows Stunning First-Line Results, but Experts Urge Caution on Treatment Order
Phase III success has made pirtobrutinib a first-line candidate for chronic lymphocytic leukemia, but resistance biology and missing reverse-sequence data ...
Adding an Antibody to Venetoclax Deepens Responses in Hard-to-Treat Lymphoma
A French retrospective study of 46 patients with relapsed or refractory Waldenström macroglobulinemia found that venetoclax combined with an anti-CD20 ...
Real-World Data Show Zanubrutinib Delivers Strong Results in 410 Leukemia Patients
A nationwide cohort of 410 patients shows zanubrutinib delivers high progression-free survival in CLL/SLL, with dose reductions and switches between ...
Ibrutinib Triggers Matriptase to Preserve CD19 and Block Antigen Escape in B-Cell Malignancy
New research shows that the BTK inhibitor ibrutinib activates the protease matriptase in malignant B cells, preserving surface CD19 and ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!